A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma

Inclusion criteria

• Signed written informed consent form.
• Age 18 to 75 years (inclusive), male or female.
• Histologically or cytologically confirmed advanced intrahepatic cholangiocarcinoma.
• Eligible participants of childbearing participants(male and female) must agree to use a reliable method of contraception during the trial and for at least 90 days after dosing; females of childbearing potential must have a negative blood pregnancy test 7 days before enrollment.

Exclusion criteria

• Participants who have received other unlisted drugs clinical trial treatment 4 weeks before the first dose of the study drug.
• Participants who underwent major organ surgery (excluding needle biopsy) or had significant trauma 4 weeks before the first dose of the study drug.
• In the herpes simplex virus recurrence and infection period, and there are corresponding clinical manifestations, such as oral herpes labialis, herpetic keratitis, herpetic dermatitis, genital herpes and so on.
• Other active uncontrolled infection.
• Known alcohol or drug dependence.
• Participants with mental disorders or poor compliance.
• Women who are pregnant or breastfeeding.
• Participants in the opinion of the investigator are not suitable for this clinical study due to other serious systemic diseases or other reasons.